Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer

Figure 1 C-mesenchymal-epithelial transition factor immunohistochemistry (20 ×) and mesenchymal-epithelial transition factor fluorescence in situ hybridization (100 ×) results. A: Mesenchymal-epithelial transition factor (MET) fluorescence in situ hybridization (FISH) positive (MET gene copy number ≥ 5 and MET/CEP7 < 2); B: MET FISH negative (MET gene copy number < 5 and MET/CEP7 < 2); C: Immunohistochemistry (IHC) 0; D: IHC 1+; E: IHC 2+; F: IHC 3+.

Figure 2 Kaplan-Meier curve of progression free survival for colorectal cancer patients in a two-year follow-up. A: Progression free survival (PFS) in colorectal cancer (CRC) patient with amplified-mesenchymal-epithelial transition factor (MET) and non-amplified MET; B: PFS in CRC patient with different c-MET protein levels. MET: Mesenchymal-epithelial transition factor; FISH: Fluorescence in situ hybridization; IHC: Immunohistochemistry.

Figure 3 Comparison between mesenchymal-epithelial transition factor fluorescence in situ hybridization and immunohistochemistry results. A: The c-mesenchymal-epithelial transition factor (MET) immunohistochemistry (IHC) status in MET fluorescence in situ hybridization positive and negative cases; B: The scatter plot representations of MET gene copy number in different c-MET IHC groups; C: The scatter plot representations of MET/CEP7 ratios in different c-MET IHC groups. MET: Mesenchymal-epithelial transition factor; GCN: Gene copy number; IHC: Immunohistochemistry.